The FDA granted priority review to a new drug application for sunvozertinib as an oral treatment for certain patients with ...

Johnson & Johnson (J&J) has reported positive topline outcomes from the Phase III MARIPOSA trial of RYBREVANT ...

Johnson & Johnson's recently approved combination of Rybrevant and Lazcluze has improved overall survival compared to ...

A meta-analysis found that peer reviews in radiation oncology led to recommendations to change treatment plans in more than ...

Luis E. Raez, MD, discusses when minimal residual disease testing can be performed as an option for patients with lung cancer.

Johnson & Johnson said on Tuesday its chemotherapy-free combination treatment showed a meaningful improvement in extending ...

Johnson & Johnson said a combination of its lung cancer drugs Rybrevant and Lazcluze kept people alive for at least a year ...

Although lung cancer survival is improving in the United States, 21% of patients with lung cancer did not receive treatment ...

Johnson & Johnson announced positive topline results for the gold standard endpoint in cancer treatment of overall survival, or OS, from ...

Johnson & Johnson’s combination of Rybrevant and Lazcluze has racked up an overall survival (OS) victory against ...

Results from the Mariposa study found a regimen of Rybrevant and Lazcluze helped patients with a common form of advanced lung ...

Lung cancer, notorious for its high mortality rates, is a leading cause of cancer-related deaths globally, with metastasis ...